Literature DB >> 8583216

Defective production of interleukin-2 in patients with idiopathic Parkinson's disease.

H Klüter1, P Vieregge, H Stolze, H Kirchner.   

Abstract

The pathogenesis of Parkinson's disease (PD) is largely unknown. Recently, several studies have presented evidence of an immunological dysfunction in patients suffering from PD. We studied the immune responsiveness of patients with idiopathic PD (n = 20) by investigation of the ability of peripheral blood mononuclear cells to produce cytokines after mitogenic stimulation in a whole blood assay. A group of age-related healthy blood donors served as control (n = 19). Additionally, white blood count, leukocyte differentiation and lymphocyte subtyping were performed. PD patients had a significantly higher neutrophil count, but analysis of T-cell subsets showed no difference between the two groups. In peripheral blood, secretion of interleukin-2 (IL-2) after mitogenic stimulation was significantly diminished in the patients' group (p < 0.01), whereas values of IFN-alpha 2, IL-6, IFN-gamma and sIL-2R were comparable in both groups. IL-2 production correlated negatively with the mean annual dose of levodopa treatment and correlated significantly (p < 0.002) with amantadine uptake. Analysis of sex, age, duration of illness and other drug intake revealed no correlation with cytokine release. Our findings support the view that there is a selective abnormality in the immune repertoire of peripheral blood lymphocytes in patients suffering from PD, the reasons for which need to be explored.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583216     DOI: 10.1016/0022-510x(95)00180-a

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

2.  Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.

Authors:  Natalia Pessoa Rocha; Frankcinéia Assis; Paula Luciana Scalzo; Érica Leandro Marciano Vieira; Izabela Guimarães Barbosa; Mariana Soares de Souza; Paulo Pereira Christo; Helton José Reis; Antonio Lucio Teixeira
Journal:  Mol Neurobiol       Date:  2017-02-07       Impact factor: 5.590

Review 3.  Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.

Authors:  Miriam Højholt Terkelsen; Ida H Klaestrup; Victor Hvingelby; Johanne Lauritsen; Nicola Pavese; Marina Romero-Ramos
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.

Authors:  M Reale; N H Greig; M A Kamal
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

Review 5.  Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.

Authors:  Natália Pessoa Rocha; Aline Silva de Miranda; Antônio Lúcio Teixeira
Journal:  Biomed Res Int       Date:  2015-07-29       Impact factor: 3.411

6.  Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis.

Authors:  K P Wandinger; K Wessel; P Neustock; A Siekhaus; H Kirchner
Journal:  J Neurol Sci       Date:  1997-07       Impact factor: 3.181

7.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

8.  Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.

Authors:  Daniel Lindqvist; Eli Kaufman; Lena Brundin; Sara Hall; Yulia Surova; Oskar Hansson
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.